574 results about "The Mycoplasmas" patented technology

Methods are disclosed for sterilizing tissue to reduce the level of one or more active biological contaminants or pathogens therein, such as viruses, bacteria, (including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia, rickettsias), yeasts, molds, fungi, spores, prions or similar agents responsible, alone or in combination, for TSEs and/or single or multicellular parasites. The methods involve sterilizing one or more tissues with irradiation.

This invention provides a trivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M. hyo) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and a PRRS virus antigen, wherein the soluble portion of the M. hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

The invention discloses a medicinal composite preparation containing quinolones, a preparation method thereof and an application thereof. The medicinal composite preparation containing quinolones comprises the following components, by mass, 0.5-95% of a quinolone medicine or a salt compound thereof, 1-97% of an organic acid or a salt compound thereof, 1-98.5% of a sweetener, 0-45% of a flavor enhancer, 0-10% of a flavoring agent, and the balance excipient. Finished products prepared from the medicinal composite preparation containing quinolones, which have the characteristics of stability, excellent dispersibility, good palatability and easy absorption, can be used as a broad-spectrum antiseptic, have the advantages of strong bactericidal activity, wide in vivo distribution and no cross drug resistance with other antibiotic medicines, and are effective to bacteria and mycoplasmas, can be used to treat various infectious diseases of the alimentary system, the respiratory system, the urinary system or the skin soft tissue of animals, wherein the diseases are caused by the sensitive bacterial or the mycoplasmas.

This invention provides an immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M.hyo) whole cell preparation, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

The invention relates to nucleic acids, methods, compositions, and kits for the PCR-based detection of Mycoplasma and Acholeplasma bacterial species. The nucleic acids, methods, compositions, and kits provide for increased specificity and sensitivity of PCR-based Mycoplasma bacterial assays. Primer sets and PCR-based assays are provided that amplify and detect conserved 16S rRNA gene sequences from multiple Mycoplasma and Acholeplasma species while avoiding amplification and detection of non-target sequences.

The invention relates to the field of pharmaceutical preparations and particularly relates to a slow-release micropill preparation containing enrofloxacin and a preparation method of the preparation. The slow-release micropill provided by the invention is formed by coating an enrofloxacin micropill; the enrofloxacin micropill comprises enrofloxacin and auxiliary material and is formed through extruding and rounding; the auxiliary material is any one or more of microcrystalline cellulose, starch, cane sugar, artificial gum, lactose and sodium carboxymethyl starch; according to weight percent, the auxiliary material in the micropill accounts for 70% to 95%; and coating is made of high-molecular enteric material, film forming material, opaquer and the like. The slow-release micropill preparation has the characteristics of slow release and high bioavailability, can be used for treating bacteria and mycoplasma infection of livestocks, and has better curative effect on chronic respiratory diseases, colibacillosis and salmonellosis, and the frequency of medicine taking can be reduced; and in addition, the slow-release micropill provided by the invention has the advantages that the stability of medicine is improved, and peculiar bitter of enrofloxacin can be covered completely, so that feeding intake of the animals is not influenced, and the recovery rate is improved.

The invention relates to a method for preparing a veterinary oxytetracycline-artemisinin injection and clinical application of the veterinary oxytetracycline-artemisinin injection. Raw materials of the injection mainly comprise oxytetracycline, artemisinin, trimethoprim, flunixin meglumine, magnesium oxide or magnesium chloride, an antioxidant, a pH regulator, a compound organic solvent and water. As a veterinary compound preparation, the veterinary oxytetracycline-artemisinin injection is mainly used for treating infectious diseases and secondary infection which are caused by sensitive gram positive bacteria and negative bacteria, eperythrozoon, rickettsia and mycoplasma. The method for preparing the veterinary compound oxytetracycline-artemisinin injection is simple, the production process is mild, the chelating temperature is low, the stability is high, and the injection is convenient to use and is suitable for industrialized production.

Diagnostic methods for the detection of SLE in a human body sample are disclosed. Nucleic acid hybridization and antibody-based methods derived from identification of Mycoplasma haemosapiens or its 16S sequence are described.

A method of expressing a protein having an unnatural amino acid integrated thereinto characterized by comprising expressing (A) a mutant tyrosyl tRNA synthase which is a mutant of Escherichia coli-origin tyrosyl tRNA synthase and has an elevated specificity for a unnatural tyrosine derivative compared with the specificity for tyrosine, (B) a suppressor tRNA originating in an eubacterium belonging to the genus Bacillus, Mycoplasma or Staphylococcus which is capable of binding to the above tyrosine derivative in the presence of the above mutant TyrRS, and (C) a desired protein gene having a nonsense mutation at a desired site in animal cells to thereby incorporate the above tyrosine derivative into the nonsense mutation site in the above protein.

The invention relates to a kit and a method for detecting mycoplasma pollution in CHO cultured cells, and belongs to the field of biological technology detection. The kit comprises a primer pair of the DNA sequence of a specific amplified CHO cell glyceraldehyde-3-phosphatedehydrogenase and a primer pair of the DNA sequence of a specific amplified mycoplasma 16srRNA conserved domain, and the two above primer pairs are placed in a same PCR system. According to the kit, when mycoplasma pollution is detected by employing the PCR technology, the determination of reliability of a detection result can be finished at the same time. The kit and the method help to substantially improve the reliability of the detection result on mycoplasma pollution in CHO cultured cells, the operation is simple, the detection period is short, and the sample detection operationality is good.

The invention belongs to the technical field of zoonosis prevention and treatment, and particularly relates to a mycoplasma bovis mutant strain with a growth defect under cell coculture and application. The mycoplasma bovis Mbov-0328 gene deletion mutant strain T9.386 is sifted out from a mycoplasma bovis gene mutant library, and the gene is coded to form cyclic dinucleotide phosphodiesterase. When the mutant strain and a bovine embryo pneumonocyte are co-cultured, the remarkable growth defect phenotype is shown; the mutant strain shows small colonial morphology on a PPLO solid culture medium.Proteomics between the mutant strain and a wild strain shows a remarkable difference expression spectrum. The mutant strain has 38 differential expression proteins, wherein 30 proteins are in up-regulated expression, and 8 proteins are in down-regulated expression. The mutant strain can be applied to the field of mycoplasma bovis metabolic physiology, pathopoiesia and immune prevention.

The invention relates to a surface enhanced Raman scattering technology-based composite material and a preparation method thereof. The composite material comprises microspheres modified with first target molecules on the surfaces and a second component modified with Raman signal molecules and second target molecule-modified polymers on the surface. In a solution containing a substance to be detected, the substance to be detected, the microspheres and the second component are bonded to the second target molecules through the first target molecules so that the composite material which can be easily precipitated through centrifugation is obtained. The invention also discloses the preparation method and a use of the composite material. The composite material can be used for detecting a human prostate-specific antigen (PSA), a human ferrohemoglobin (Hb), a procalcitonin (PCT) or disease markers (such as tumor markers, cardiovascular disease markers, senile dementia markers, mycoplasma and chlamydia), can effectively reduce false positive and false negative effects and has advantages of high sensitivity, simpleness, fastness and low cost.

The invention discloses a fusion protein of a mycoplasma pneumonia protein epitope and preparation and application thereof, and relates to the fields of genetic engineering technologies, vaccines and diagnosis reagents. Amino acid sequences of a mycoplasma pneumoniae P116 protein, a P1 protein and a P30 protein are analyzed through a computer, mycoplasma pneumoniae P116 protein fragments, namely from the 261st amino acid to the 466th amino acid containing the strong epitope, mycoplasma pneumoniae P1 protein fragments, namely from the 1125th amino acid to the 1395th amino acid containing the strong epitope and mycoplasma pneumoniae P30 protein fragments, namely from the 107th amino acid to the 161st amino acid containing the strong epitope are screened out. Series connection gene sequences of novel mycoplasma pneumoniae P116 protein fragments, mycoplasma pneumoniae P1 protein fragments and mycoplasma pneumoniae P30 protein fragments are synthesized chemically, three gene fragments are connected in series, the fusion protein of P116 protein fragments, P1 protein fragments and P30 protein fragments is expressed by means of the genetic engineering technology, the three protein fragments are connected through glycine-glycine-serine, and 538 amino acids are formed in the overall length of the fusion protein.

The invention belongs to the field of animal gene engineering, and in particular relates to a synthetic fusion gene for expressing mycoplasma hyopneumoniae and application. The fusion gene is characterized in that a mycoplasma hyopneumoniae P97R1 gene is connected in series with a P36 gene through a Linker, the termination codon of the P36 gene is deleted, the P46 gene with signal peptide removed is fused at the C end of the P36 gene through Linker, and then the fusion gene P97R1-P36-P46 is obtained, wherein the nucleotide sequence of the fusion gene is shown as SEQ ID NO: 1. The fusion gene is included in a prokaryotic expression plasmid, and escherichia coli BL21/pET30a-P97R1-Linker-P36-Linker-P46 containing the plasmid is collected in CCTCC with the collection number CCTCC NO: M2014269. The invention further discloses immune efficacy evaluation of the fusion gene and application of the fusion gene in a novel vaccine.

The invention discloses a raw material composition of a kit for loop-mediated isothermal amplification (LAMP) detection of Mycoplasma ovipneumoniae and a preparation method and a usage method of the kit. The raw material composition comprises 1000-2000muL of reaction solution, 100-200muL of Bst (Bacillus stearothermophilus) DNA polymerase, 50-100muL of positive control, 50-100muL of negative control, 1-2mL of liquid paraffin and 1-2mL of ultrapure water. The reaction solution comprises an inner primer mixture solution, an outer primer mixture solution, an LAMP reaction buffer, Mg<2+> and dNTPs (deoxyribonucleotide triphosphates), wherein the volume ratio of the five liquids in the reaction solution is 2:2:2.5:2:1. The preparation method comprises the following steps: 1) determination of an optimum reaction temperature and an optimum reaction time; 2) specific detection, sensibility test and clinical application detection and 3) kit packaging. The kit disclosed by the invention has rapid, simple and accurate characteristics for pathogen detection of goat suspected cases of mycoplasma ovipneumoniae infection in goat farms.

The invention relates to the technical field of genetic engineering, in particular to a primer and probe combination for simultaneously detecting various kinds of bacteria and mycoplasmas. The invention also provides a multiplex PCR detection method for simultaneously detecting various kinds of bacteria and mycoplasmas. When the method is used, various kinds of bacteria and mycoplasmas can be detected at the same time; multiplex detection is realized; the sensitivity is high; high speed and convenience are realized; and the batch detection on samples can be realized. The invention also provides a kit for simultaneously detecting various kinds of bacteria and mycoplasmas and application thereof. Various technical problems of common infectious pathogenic microorganism detection in clinics are solved.

The present invention relates to inactivated mixed vaccine for preventing porcine respiratory disease. The inactivated mixed vaccine of the present invention, which comprises a certain amount of inactivated Haemophilus parasuis S4 and S5, Mycoplasma hyopneumoniae , and PRRS virus, can effectively prevent porcine respiratory disease such as Glasser's disease, Swine enzootic pneumonia and PRRS. Further, the mixed vaccine of the present invention can prevent progress of the porcine respiratory disease to PRDC (Porcine Respiratory Disease Complex) and PMWS (Post-weaning Multisystemic Wasting Syndrome).